Only 5% of these US specialists say their practices plan to hold off until Labor Day or later before resuming elective procedures.
Yet only 40% say that their facilities are prepared for a second wave or any local outbreaks caused by the states re-opening.
These are findings from the InCrowd Novel Coronavirus (COVID-19) Non-Frontline Treating Physician Tracking Report--Wave 2, a snapshot of US physician sentiments from oncologists, neurologists, rheumatologists, cardiologists, gastroenterologists, and dermatologists conducted and sourced by InCrowd, a provider primary market intelligence for the life science industry.
With recent spikes in COVID-19 cases forcing curtailment to elective procedures in some hard-hit communities, InCrowd's new findings document significant care delivery progress along with lingering perceived issues in governmental preparedness.
Fifty-four percent reported that their facilities are currently strongly prepared to treat COVID-19 patients.
Physician concerns over personal/familial safety and markers of mental health have all improved significantly since April, with concerns over safety dropping by over 20 %age points, to 48% of respondents, down from 71% in April. Concerns related to job security reducing by over a third, to 13% of respondents, down from 22% in April.
The number of specialists experiencing frequent patient cancellations for routine appointments has dropped by nearly half of what was reported in April, to just 37% in June, from 73% in April. Fewer physicians noted difficulty in prescribing medications for patients, compared to 20% in April.
Ninety-one percent use virtual visits or telehealth TODAY, and more than a third said they plan on using telehealth for routine appointments moving forward.
Nearly 30% plan to use it for preparatory appointments for upcoming surgeries and 26% will use telehealth for screening patients for urgent visits.
However, only 46% said their increased use of telehealth is likely to continue after the crisis is over, down slightly from 52% in April.
A third of specialists write-in that in order to make patients feel safe, their facilities require a negative COVID-19 test before admitting anyone. More than two-thirds report they are planning to continue practicing better hygiene, limit physical contact such as handshakes, require social distancing, and screen patients before visits.
In verbatim remarks physicians emphasized rigorous sanitization and other changed office practices they share with patients to keep them safe--from "advising [patients] of the number of patients at the height of COVID in hospital and [the] number now," to "asking patients to comply with pre-procedural [COVID-19] testing."
Overall, non-frontline physicians do not find that the US is taking sufficient precautions, with approval of the federal government's management of the pandemic at 18%, nearly half that of international governments.
Only one-in-five believes the US has the ability to flatten the curve. Respondents were more bullish on their state government and local government preparedness.
Meetings with pharma sales reps will be limited or deferred, despite 18% of respondents saying that COVID-19 has made it more difficult to become aware of medications that could help their patients.
Only 22% envision booking telehealth-style virtual meetings with pharma reps, with 31% expecting to wait until 2021 before allowing in-person meetings.
On average, non-frontline physicians estimate that things will not return to normal for another nine months--not until March of next year. One third cite that disruptions will continue until a vaccine is developed and disseminated.
InCrowd's Novel Coronavirus (COVID-19) Non-Frontline Treating Physician Tracking Report--Wave 2, included the perceptions of n=201 US physicians, including 103 practicing in offices, and 98 practicing in hospitals.
Total respondents included oncologists, neurologists, rheumatologists, gastroenterologists, cardiologists, and dermatologists. The 7-minute MicroSurvey for Wave 2 fielded June 12-13, 2020.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA